The Motley Fool Previous Page

Pfizer Bulks Up Before the Breakup

Brian Orelli, Ph.D.
August 14, 2012

It's looking increasingly less likely that Pfizer (NYSE: PFE  ) will spin out or sell its consumer health division. Yesterday, the pharma giant licensed the rights to sell an over-the-counter version of AstraZeneca's (NYSE: AZN  ) Nexium.

The price tag wasn't cheap: $250 million plus milestones and royalty payments based on product launches and sales. Of course, the prescription version of the purple pill raked in nearly $8 billion globally last year, so assuming Pfizer can persuade regulatory